Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug interaction study for myelofibrosis treatment completed

NCT ID NCT06024915

First seen Jan 06, 2026 · Last updated Jun 22, 2026 · Updated 25 times

Summary

This phase 1 trial tested how TQ05105 tablets, a drug for myelofibrosis, interact with other drugs that affect liver enzymes. 40 healthy adults took TQ05105 alone and with itraconazole or rifampicin. Researchers measured drug levels and safety to understand how these combinations change the drug's effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Shandong Provincial Hospital

    Jinan, Shandong, 250021, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TQ05105 tablets (a JAK2 inhibitor)

What this could lead to

If successful, this study will show how TQ05105 interacts with other drugs, helping doctors use it safely for myelofibrosis.

What could go wrong

This is a very early, small study in healthy people, not patients. It only tests drug interactions, not whether TQ05105 works for myelofibrosis.

Conditions

The condition(s) this trial relates to.

primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.